Dr. Lilly Immergluck is Associate Professor of Pediatrics at Morehouse School of Medicine and Pediatric Infectious Disease Specialist with Children’s Healthcare of Atlanta. Dr. Immergluck also holds a joint appointment as Assistant Professor in the Department of Microbiology/Biochemistry/Immunology at Morehouse School of Medicine.
She received her B.A. degree from Northwestern University in Evanston, Illinois and received her medical degree from Ohio State University College of Medicine in 1990. She completed her residency in Pediatrics at the University of Chicago Children’s Hospital and also completed a fellowship in Pediatric Infectious Diseases at the University of Chicago. She was a recipient of the Pediatric Scientist Development Award in 1994, where she developed a primary neuronal model to study requirements for herpes simplex entry. In 2012, she received her Master’s of Science in Clinical Research.
Prior to relocating to Atlanta in 2005, she was Assistant Professor of Pediatrics at the University of Illinois at Chicago from 1996-2002 and then Associate Professor of Pediatrics at Michigan State University and was Director of the Pediatric Infectious Diseases Program at DeVos Children’s Hospital from 2002-2005. For the past 15 years her clinical research endeavors have focused primarily on elucidating the risk factors and understanding the epidemiology of children who have been colonized or infected by the resistant bacterium, community-associated methicillin resistant Staphylococcus aureus (or CA-MRSA). She has an interest in hospital epidemiology and also public health matters as it relates to the prevention of infectious diseases among medically underserved populations and vaccine preventable conditions, including rotavirus, influenza, and pneumococcus. She currently is site director of the MRSA Treatment Center in Atlanta, which is part of a national NIH funded multi-center clinical trial to look at treatment options for uncomplicated skin and soft tissue infections and also is involved to look at the impact of rotavirus vaccinations on eliminating rotaviral related illnesses among infants and young children in the US.